Molecular modeling-driven approach for identification of Janus kinase 1 inhibitors through 3D-QSAR, docking and molecular dynamics simulations

References

• Yoshiya T, Shigeru I, Kunihiro Y. Jak and Syk: emerging their relevance to the treatment of inflammatory diseases. Inflamm Regen 2011;31:237.
   Google Scholar
• O'Shea JJ, Pesu M, Borie DC, et al. A new modality for immunesuppression: targeting the JAK/STAT pathway. Nat Rev Drug Discov 2004;3:555–64.
   PubMed Web of Science ®Google Scholar
• Malemud CJ, Pearlman E, Current signal transduction therapy. Targeting JAK/STAT signaling pathway in inflammatory diseases. the Netherlands: Bentham Science; 2009.
   Google Scholar
• Ghoreschi K, Laurence A, O'Shea JJ. Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat Immunol 2009; 10:356–60.
   PubMed Web of Science ®Google Scholar
• Kisseleva T, Bhattacharya S, Braunstein J, et al. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 2002;285:1–24.
   PubMed Web of Science ®Google Scholar
• Igaz P, Tóth S, Falus A. Biological and clinical significance of the JAK-STAT pathway; lessons from knockout mice. Inflamm Res 2001;50:435–41.
   PubMed Web of Science ®Google Scholar
• Leonard WJ, O'Shea JJ. JAKS AND STATS: biological implications. Annu Rev Immunol 1998;16:293–322.
   PubMed Web of Science ®Google Scholar
• Christian S, David EL, Thomas D. JAK-STAT signaling: from interferons to cytokines. J Biol Chem 2007;282:20059–63.
   PubMed Web of Science ®Google Scholar
• Levy DE, Darnell JE. Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002;3:651–62.
   PubMed Web of Science ®Google Scholar
• Stump KL, Lu LD, Dobrzanski P, et al. A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis. Arthritis Res Ther 2011;13:R68.
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Hagop K, Jorge C, et al. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 2011;10:127–40.
   PubMed Web of Science ®Google Scholar
• Róbert K, Peter PS, György MK. Recent developments on JAK2 inhibitors: a patent review. Expert Opin Ther Pat 2010;20:471–95.
   PubMed Web of Science ®Google Scholar
• Domanska D, Brzezianska E. The JAK/STAT protein activation – role in cancer development and targeted therapy. Curr Signal Transduct Ther 2012;7:187–201.
   Web of Science ®Google Scholar
• O’Shea JJ, Matthew H, Denise L, et al. Jak3 and the pathogenesis of severe combined immunodeficiency. Mol Immunol 2004;41:727–37.
   PubMed Web of Science ®Google Scholar
• Malemud CJ. Dysfunctional immune-mediated inflammation in rheumatoid arthritis dictates that development of anti-rheumatic disease drugs target multiple intracellular signaling pathways. Anti-inflamm Antiallergy Agents Med Chem 2011;10:78–84.
   PubMedGoogle Scholar
• West k. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Curr Opin Investig Drugs 2009;10:491–504.
   Google Scholar
• Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009;60:1895–905.
   PubMed Web of Science ®Google Scholar
• FDA has approved tofacitinib for rheumatoid arthritis: Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm327152.html [last accessed 6 Nov 2012].
   Google Scholar
• Clemens S, Josef S, Uma Y, et al. In January 2009, tocilizumab (RoActemra; Chugai/Roche), a humanized monoclonal antibody that binds to the interleukin-6 receptor, was granted marketing authorization by the European Commission for the treatment of moderate to severe rheumatoid arthritis. Nat Rev Drug Discov. 2009;8: 273–274.
   Google Scholar
• Rodig SJ, Meraz MA, White JM, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998;93:373–83.
   Google Scholar
• Shimoda K, Kato K, Aoki K, et al. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity 2000;13:561–71.
   PubMed Web of Science ®Google Scholar
• Parganas E, Wang D, Stravopodis D. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998;93:385–95.
   PubMed Web of Science ®Google Scholar
• Claude H, Catherine R, Friedrich R, et al. Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors. Chem Bio 2011;18:314–23.
   PubMedGoogle Scholar
• Song L, Schindler C, The handbook of cell signalling: JAK-STAT signaling. 2nd ed. San Diego: Elsevier; 2010.
   Google Scholar
• Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J. Biol. Chem 2007; 282:20059–63.
   PubMed Web of Science ®Google Scholar
• Caflisch A, Ehrhardt C, Structure based drug design: structure-based combinatorial ligand design. New York: Marcel Dekker; 1997.
   Google Scholar
• Cho SJ, Garsia MLS, Bier J, et al. Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J.Med.Chem 1996;39:5064–71.
   PubMed Web of Science ®Google Scholar
• Sippl W, Contreras JM, Parrot I, et al. Structure-based 3D QSAR and design of novel acetylcholinesterase inhibitors. J Comput Aided Mol Des 2001;15:395–410.
   PubMed Web of Science ®Google Scholar
• Sippl W. Receptor-based 3D QSAR analysis of estrogen receptor ligands merging the accuracy of receptor-based alignments with the computational efficiency of ligand-based methods. J Comput Aided Mol Des 2000;14:559–72.
   PubMed Web of Science ®Google Scholar
• Cramer RD, 3rd, Patterson DE, Bunce JD. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 1988;110:5959–67.
   PubMed Web of Science ®Google Scholar
• Cramer RD, 3rd, Patterson DE, Bunce JD. Cross validation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. Quant Struct Act Relat 1998;7:18–25.
   Google Scholar
• Klebe G, Abraham U, Mietzer T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 1994;37:4130–46.
   PubMed Web of Science ®Google Scholar
• Wold S, Johansson A, Cochi M, 3D-QSAR in drug design: theory, methods and application: PLS-Partial least squares projection to latent structures.in. Germany: ESCOM; 1993.
   Google Scholar
• Janusz JK, Wade B, Richard JB, et al. Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors. J Med Chem 2012;55:5901–21.
   PubMed Web of Science ®Google Scholar
• Mark Z, Rohan M, Mercedesz B, et al. Discovery and optimization of C-2 methyl imidazo-pyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2. J Med Chem 2012;55:6176–93.
   PubMed Web of Science ®Google Scholar
• Labadie S, Dragovich PS, Barrett K, et al. Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2. Bioorg Med Chem Lett 2012;22:7627–33.
   PubMed Web of Science ®Google Scholar
• Hurley CA, Blair WS, Bull RJ, et al. Novel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1. Bioorg Med Chem Lett 2013;23:3592–8.
   PubMed Web of Science ®Google Scholar
• Zak M, Hurley CA, Ward SI, et al. Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2. J Med Chem 2013;56:4764–85.
   PubMed Web of Science ®Google Scholar
• Williams NK, Bamer RS, Patel O, et al. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J Mol Biol 2009;387:219–32.
   PubMed Web of Science ®Google Scholar
• Schrödinger LLC. New York Glide Version 5.6; 2010.
   Google Scholar
• Friesner RA, Banks JL, Murphy RB, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004;47:1739–49.
   PubMed Web of Science ®Google Scholar
• Fatima S, Raju B, Sree Kanth S, et al. Molecular docking and 3D-QSAR studies on inhibitors of DNA damage signaling enzyme human PARP-1. J Recep Signal Transduc 2012;32:214–24.
   PubMed Web of Science ®Google Scholar
• Sybyl-X 2.1. St. Louis, MO: Tripos Associates; 2012.
   Google Scholar
• Gasteiger J, Marsili M. Iterative partial equalization of orbital electronegativity—a rapid access to atomic charges. Tetrahedron 1980;36:3219–28.
   Web of Science ®Google Scholar
• Schrödinger LLC. Qikprop, version 3.4, New York; 2010.
   Google Scholar
• D. E. Shaw Research. Desmond 3.8. New York: D. E. Shaw Research; 2014.
   Google Scholar
• Kaminski GA, Friesner RA. Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. J Phys Chem 2001;105:6474–87.
   Web of Science ®Google Scholar
• Berendsen HJC, Grigera JR, Straatsma TP. The missing term in effective pair potentials. J Phys Chem 1987;91:6269–71.
   Web of Science ®Google Scholar
• Ramesh I, Srilata B, Sree KS, et al. Molecular docking, 3D QSAR and dynamics simulation studies of imidazo-pyrrolopyridines as janus kinase 1 (JAK 1) inhibitors. Comput Bio Chem 2016;64:33–46.
   PubMed Web of Science ®Google Scholar
• Saikiran RP, Sree KS, Vijjulatha M, Molecular Dynamics and MM/GBSA integrated protocol probing the correlation between biological activities and binding free energies of HIV-1 TAR RNA inhibitors.2017. Available from: http://dx.doi.org/10.1080/07391102.2017.1281762 [last accessed 2017 Feb 1].
   Google Scholar
• Sree Kanth S, Vijjulatha M. Molecular docking and 3D-QSAR studies on triazolinone and pyridazinone, non-nucleoside inhibitor of HIV-1 reverse transcriptase. J Mol Mod 2010;16:1169–78.
   PubMed Web of Science ®Google Scholar